Immunome Stock Performance
| IMNM Stock | USD 9.82 0.40 4.25% |
The company retains a Market Volatility (i.e., Beta) of 2.12, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunome will likely underperform. At this point, Immunome has a negative expected return of -0.64%. Please make sure to check out Immunome's potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Immunome performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunome has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 4.25 | Five Day Return (3.73) | Year To Date Return (10.81) | Ten Year Return (26.99) | All Time Return (26.99) |
1 | Acquisition by Lamattina John L of 6500 shares of Immunome at 4.84 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 14380 shares by Max Rosett of Immunome at 16.01 subject to Rule 16b-3 | 09/19/2024 |
3 | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/08/2024 |
4 | Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 | 10/29/2024 |
5 | Illumina Tops Q3 Earnings and Revenue Estimates | 11/04/2024 |
6 | Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference | 11/05/2024 |
7 | TELA Bio, Inc. Reports Q3 Loss, Lags Revenue Estimates | 11/07/2024 |
8 | Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/13/2024 |
9 | Janus Henderson Groups Strategic Acquisition of Immunome Inc Shares | 11/14/2024 |
10 | Immunome files to sell 1.80M shares of common stocks by selling shareholders | 11/22/2024 |
| Begin Period Cash Flow | 20.4 M |
Immunome |
Immunome Relative Risk vs. Return Landscape
If you would invest 1,571 in Immunome on August 25, 2024 and sell it today you would lose (589.00) from holding Immunome or give up 37.49% of portfolio value over 90 days. Immunome is currently does not generate positive expected returns and assumes 3.9441% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Immunome, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunome Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunome's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunome, and traders can use it to determine the average amount a Immunome's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1631
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMNM |
Estimated Market Risk
| 3.94 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.64 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunome is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunome by adding Immunome to a well-diversified portfolio.
Immunome Fundamentals Growth
Immunome Stock prices reflect investors' perceptions of the future prospects and financial health of Immunome, and Immunome fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunome Stock performance.
| Return On Equity | -2.76 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (15.06) % | ||||
| Current Valuation | 375.52 M | ||||
| Shares Outstanding | 62.42 M | ||||
| Price To Book | 2.74 X | ||||
| Price To Sales | 60.51 X | ||||
| Revenue | 14.02 M | ||||
| EBITDA | (28.27 M) | ||||
| Net Income | (106.81 M) | ||||
| Cash And Equivalents | 34.65 M | ||||
| Cash Per Share | 2.86 X | ||||
| Total Debt | 1.65 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 4.97 X | ||||
| Cash Flow From Operations | (7.57 M) | ||||
| Earnings Per Share | (7.94) X | ||||
| Market Capitalization | 612.93 M | ||||
| Total Asset | 148.54 M | ||||
| Retained Earnings | (222.81 M) | ||||
| Working Capital | 122.87 M | ||||
About Immunome Performance
By examining Immunome's fundamental ratios, stakeholders can obtain critical insights into Immunome's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Immunome is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (563.44) | (591.61) | |
| Return On Tangible Assets | (0.72) | (0.75) | |
| Return On Capital Employed | (0.86) | (0.91) | |
| Return On Assets | (0.72) | (0.75) | |
| Return On Equity | (0.89) | (0.94) |
Things to note about Immunome performance evaluation
Checking the ongoing alerts about Immunome for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunome help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunome generated a negative expected return over the last 90 days | |
| Immunome has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 14.02 M. Net Loss for the year was (106.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunome currently holds about 34.65 M in cash with (7.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86. | |
| Immunome has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Immunome files to sell 1.80M shares of common stocks by selling shareholders |
- Analyzing Immunome's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunome's stock is overvalued or undervalued compared to its peers.
- Examining Immunome's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunome's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunome's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunome's stock. These opinions can provide insight into Immunome's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.